Melan-A Antibody (0.N.397): sc-71569
- Melan-A Antibody (0.N.397) is a mouse monoclonal IgG2b provided at 200 µg/ml
- raised against recombinant Melan-A of human origin
- recommended for detection of Melan-A of mouse, rat and human origin by WB, IP, IF and IHC(P)
- See Melan-A (A103): sc-20032 for Melan-A antibody conjugates, including AC, HRP, FITC, PE, Alexa Fluor® 488, 594, 647, 680 and 790.
- At present, we have not yet completed the identification of the preferred secondary detection reagent(s) for Melan-A Antibody (0.N.397). This work is in progress.
QUICK LINKS
SEE ALSO...
Melan-A Antibody (0.N.397) is a mouse monoclonal IgG2b antibody that detects Melan-A in mouse, rat, and human samples through applications such as western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), and immunohistochemistry. Melan-A, also known as MART-1, is a melanocyte differentiation antigen that plays a crucial role in the immune response against melanoma, as Melan-A is specifically expressed in melanomas, melanocyte cell lines, and the retina. The significance of Melan-A (0.N.397) antibody lies in detecting proteins recognized by HLA-A2-restricted tumor-infiltrating lymphocytes, which are essential for targeting and eliminating melanoma cells. This interaction highlights Melan-A′s potential as a target for cancer immunotherapy, as cytotoxic T lymphocytes can be generated using Melan-A peptides, thereby enhancing the immune system′s ability to combat melanoma. Anti-Melan-A antibody (0.N.397) enables researchers to explore the mechanisms of melanoma progression and the development of effective immunotherapeutic strategies.
Alexa Fluor® is a trademark of Molecular Probes Inc., OR., USA
LI-COR® and Odyssey® are registered trademarks of LI-COR Biosciences
Melan-A Antibody (0.N.397) References:
- Immunoprofile of MITF, tyrosinase, melan-A, and MAGE-1 in HMB45-negative melanomas. | Xu, X., et al. 2002. Am J Surg Pathol. 26: 82-7. PMID: 11756773
- Peptide-specific CD8+ T-cell evolution in vivo: response to peptide vaccination with Melan-A/MART-1. | Jäger, E., et al. 2002. Int J Cancer. 98: 376-88. PMID: 11920589
- Encapsulation into sterically stabilised liposomes enhances the immunogenicity of melanoma-associated Melan-A/MART-1 epitopes. | Adamina, M., et al. 2004. Br J Cancer. 90: 263-9. PMID: 14710238
- Computational peptide dissection of Melan-a/MART-1 oncoprotein antigenicity. | Tiwari, R., et al. 2004. Peptides. 25: 1865-71. PMID: 15501517
- Melanoma-associated antigen tyrosinase but not Melan-A/MART-1 expression and presentation dissociate during the heat shock response. | Milani, V., et al. 2005. Int Immunol. 17: 257-68. PMID: 15642953
- Establishment of a screening system for chemicals that upregulate a melanoma antigen, Melan-A/MART-1. | Song, HZ., et al. 2009. Tohoku J Exp Med. 217: 231-7. PMID: 19282659
- Identification of an HLA-DPB1*0501 restricted Melan-A/MART-1 epitope recognized by CD4+ T lymphocytes: prevalence for immunotherapy in Asian populations. | Meng, Z., et al. 2011. J Immunother. 34: 525-34. PMID: 21760531
- Circulating CD4+ T cells that produce IL4 or IL17 when stimulated by melan-A but not by NY-ESO-1 have negative impacts on survival of patients with stage IV melanoma. | Zelba, H., et al. 2014. Clin Cancer Res. 20: 4390-9. PMID: 24938524
- Melan-A immunolabeling in canine extramedullary plasmacytomas. | Schuwerk, L., et al. 2024. Vet Pathol. 61: 904-911. PMID: 38642035
- Immunoreactivity for A103, an antibody to melan-A (Mart-1), in adrenocortical and other steroid tumors. | Busam, KJ., et al. 1998. Am J Surg Pathol. 22: 57-63. PMID: 9422316
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Melan-A Antibody (0.N.397) | sc-71569 | 200 µg/ml | $316.00 |